This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Click on the following links to related sections within the document: Injection Instructions.
aData on File (Paliperidone Palmitate 1-Month CCDS).1
CLINICAL DATA
In clinical studies,2,3 INVEGA SUSTENNA was administered in either the deltoid or gluteal injection site. For the deltoid site, the needle was injected at a 90 degree angle to the skin with a quick thrust, inserting the needle into the thickest portion of the deltoid muscle, above the level of the axilla and below the acromion. For the gluteal site, the junction of the posterior iliac crest and sacrum was palpated to draw an imaginary line to the greater trochanter of the femur. Injection was given in the upper outer area bordered by this imaginary triangle. See Figure: Guidelines for Intramuscular Injection of INVEGA SUSTENNA
Guidelines for Intramuscular Injection of INVEGA SUSTENNA2,3
Literature Search
A literature search of Ovid MEDLINE®, Embase, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 19 December 2024.
| 1 | Data on File. Paliperidone Palmitate 1-Month CCDS. Janssen Research & Development, LLC. |
| 2 | Data on File. Paliperidone Palmitate 1-Month. Clinical Protocol R092670-SCA-3004. Ortho-McNeil Janssen Scientific Affairs, LLC. EDMS-ERI-13472379. |
| 3 | Data on File. Paliperidone Palmitate 1-Month. Protocol R092670SCH3006; Phase 4. Janssen Scientific Affairs, LLC. EDMS-ERI-13455124. |
